Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation

BackgroundDiabetic Nephropathy (DN), a major microvascular complication of diabetes, poses challenges for current treatments to effectively delay its progression. Wulingsan (WLS), a traditional Chinese medicine formula, possesses potential for regulating water-fluid metabolism, and exhibits anti-inf...

Full description

Saved in:
Bibliographic Details
Main Authors: Xicheng Hu, Zhen Wang, Liyan Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2025.1647796/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849245745783242752
author Xicheng Hu
Zhen Wang
Liyan Zhang
author_facet Xicheng Hu
Zhen Wang
Liyan Zhang
author_sort Xicheng Hu
collection DOAJ
description BackgroundDiabetic Nephropathy (DN), a major microvascular complication of diabetes, poses challenges for current treatments to effectively delay its progression. Wulingsan (WLS), a traditional Chinese medicine formula, possesses potential for regulating water-fluid metabolism, and exhibits anti-inflammatory and antioxidant properties, yet its multi-target mechanism in treating DN remains unclear. This study aims to systematically elucidate the molecular mechanisms of WLS in the treatment of DN through network pharmacology, molecular docking, and in vitro experiments.MethodsActive ingredients of WLS and their targets were screened using the TCMSP database, while DN-related targets were obtained from the GeneCards and OMIM databases to construct an “ingredient-target-disease” network. GO and KEGG pathway enrichment analyses were performed using DAVID to identify key biological processes and signaling pathways. A protein-protein interaction (PPI) network was constructed via the STRING database, and key targets were screened using the CytoHubba plugin. Subsequently, molecular docking and molecular dynamics simulations were conducted to validate the binding affinity and stability of active ingredients with key targets. In vitro, a high glucose-induced HK-2 cell model was employed, and the effects of WLS on cell viability and cell cycle were assessed using CCK-8 assays and flow cytometry, respectively.ResultsThe study screened and identified SRC, AKT1, TNF, ESR1, and HSP90AA1 as key targets for the treatment of DN. KEGG enrichment analysis revealed that WLS primarily regulates signaling pathways such as PI3K-Akt and MAPK, which are closely associated with inflammation, oxidative stress, and fibrosis. Molecular docking indicated that active ingredients (β-caryophyllene, alisol C) exhibited binding energies below −5.0 kcal/mol with key targets (TNF, HSP90AA1), and molecular dynamics simulations further validated their binding stability. In vitro experiments demonstrated that WLS significantly inhibited the proliferation of high glucose-induced HK-2 cells (P < 0.01) and induced G2/M phase cell cycle arrest (P < 0.01).ConclusionWulingsan alleviates the progression of Diabetic Nephropathy by its multiple active ingredients acting synergistically on key targets such as SRC, AKT1, and TNF, thereby regulating PI3K-Akt and MAPK signaling pathways to inhibit inflammation, oxidative stress, and fibrosis. This research provides a theoretical basis for the clinical application of WLS, and its therapeutic efficacy warrants further verification through future in vivo experiments.
format Article
id doaj-art-49e26ac82a71480dbd02b2347a6e1e6d
institution Kabale University
issn 2296-889X
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Molecular Biosciences
spelling doaj-art-49e26ac82a71480dbd02b2347a6e1e6d2025-08-20T03:58:44ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2025-07-011210.3389/fmolb.2025.16477961647796Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validationXicheng Hu0Zhen Wang1Liyan Zhang2Department of Traditional Chinese Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaDepartment of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, Hebei, ChinaBackgroundDiabetic Nephropathy (DN), a major microvascular complication of diabetes, poses challenges for current treatments to effectively delay its progression. Wulingsan (WLS), a traditional Chinese medicine formula, possesses potential for regulating water-fluid metabolism, and exhibits anti-inflammatory and antioxidant properties, yet its multi-target mechanism in treating DN remains unclear. This study aims to systematically elucidate the molecular mechanisms of WLS in the treatment of DN through network pharmacology, molecular docking, and in vitro experiments.MethodsActive ingredients of WLS and their targets were screened using the TCMSP database, while DN-related targets were obtained from the GeneCards and OMIM databases to construct an “ingredient-target-disease” network. GO and KEGG pathway enrichment analyses were performed using DAVID to identify key biological processes and signaling pathways. A protein-protein interaction (PPI) network was constructed via the STRING database, and key targets were screened using the CytoHubba plugin. Subsequently, molecular docking and molecular dynamics simulations were conducted to validate the binding affinity and stability of active ingredients with key targets. In vitro, a high glucose-induced HK-2 cell model was employed, and the effects of WLS on cell viability and cell cycle were assessed using CCK-8 assays and flow cytometry, respectively.ResultsThe study screened and identified SRC, AKT1, TNF, ESR1, and HSP90AA1 as key targets for the treatment of DN. KEGG enrichment analysis revealed that WLS primarily regulates signaling pathways such as PI3K-Akt and MAPK, which are closely associated with inflammation, oxidative stress, and fibrosis. Molecular docking indicated that active ingredients (β-caryophyllene, alisol C) exhibited binding energies below −5.0 kcal/mol with key targets (TNF, HSP90AA1), and molecular dynamics simulations further validated their binding stability. In vitro experiments demonstrated that WLS significantly inhibited the proliferation of high glucose-induced HK-2 cells (P < 0.01) and induced G2/M phase cell cycle arrest (P < 0.01).ConclusionWulingsan alleviates the progression of Diabetic Nephropathy by its multiple active ingredients acting synergistically on key targets such as SRC, AKT1, and TNF, thereby regulating PI3K-Akt and MAPK signaling pathways to inhibit inflammation, oxidative stress, and fibrosis. This research provides a theoretical basis for the clinical application of WLS, and its therapeutic efficacy warrants further verification through future in vivo experiments.https://www.frontiersin.org/articles/10.3389/fmolb.2025.1647796/fullWulingsandiabetic nephropathynetwork pharmacologymolecular dockingexperimental validation
spellingShingle Xicheng Hu
Zhen Wang
Liyan Zhang
Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
Frontiers in Molecular Biosciences
Wulingsan
diabetic nephropathy
network pharmacology
molecular docking
experimental validation
title Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
title_full Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
title_fullStr Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
title_full_unstemmed Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
title_short Investigating potential targets of Wulingsan in diabetic nephropathy through network pharmacology and experimental validation
title_sort investigating potential targets of wulingsan in diabetic nephropathy through network pharmacology and experimental validation
topic Wulingsan
diabetic nephropathy
network pharmacology
molecular docking
experimental validation
url https://www.frontiersin.org/articles/10.3389/fmolb.2025.1647796/full
work_keys_str_mv AT xichenghu investigatingpotentialtargetsofwulingsanindiabeticnephropathythroughnetworkpharmacologyandexperimentalvalidation
AT zhenwang investigatingpotentialtargetsofwulingsanindiabeticnephropathythroughnetworkpharmacologyandexperimentalvalidation
AT liyanzhang investigatingpotentialtargetsofwulingsanindiabeticnephropathythroughnetworkpharmacologyandexperimentalvalidation